Humana (HUM) vs Natera (NTRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Humana (HUM) has outperformed Natera (NTRA) over the past year, gaining 71.7% versus a gain of 18.5%. Over five years, NTRA leads with a +188.8% price change compared with -9.0% for HUM. Humana is the larger company by market cap ($46.84 billion vs $39.64 billion), about 1.2 times the size, while Natera is growing revenue faster (+35.9% vs +10.1%).
Humana pays a dividend yielding 0.91%, while Natera does not currently pay one. Humana converts more of its revenue into profit, with a net margin of 0.9% versus -9.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUM | NTRA |
|---|---|---|
| Share price | $390.00 | $273.40 |
| Market cap | $46.84B | $39.64B |
| 1-day change | +2.63% | -5.70% |
| YTD return | +52.27% | +19.34% |
| 1-year return | +71.73% | +18.54% |
| 5-year return | -8.98% | +188.82% |
| P/E ratio (TTM) | 38.05 | — |
| Forward P/E | 21.06 | — |
| EPS (TTM) | $10.25 | $-1.12 |
| Dividend yield | 0.91% | 0.00% |
| Annual dividend | $3.54 | $0.00 |
| Revenue (latest FY) | $129.66B | $2.31B |
| Revenue growth (YoY) | +10.11% | +35.90% |
| Net income (latest FY) | $1.19B | $-208.16M |
| Operating margin | 2.09% | -13.44% |
| Net margin | 0.92% | -9.03% |
| 52-week high | $462.87 | $437.41 |
| 52-week low | $163.11 | $181.00 |
| Distance from 52-week high | -15.74% | -37.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +30.98% | +50.06% |
| Average volume | 1.46M | 1.77M |
| Shares outstanding | 120.10M | 145.00M |
| Employees | 67,060 | 6,135 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HUM has outperformed NTRA by 53.2 percentage points over the past year.
- Humana is more profitable, keeping 0.9 cents of every revenue dollar as net income versus -9.0 cents for Natera.
- Natera grew revenue faster in its latest fiscal year (+35.90% vs +10.11%).
About Humana
HUM stock →Humana Inc. provides medical and specialty insurance products in the United States.
Health Care · Medical Specialities · 67,060 employees
About Natera
NTRA stock →Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Health Care · Medical Specialities · 6,135 employees
HUM vs NTRA FAQ
Which is bigger, Humana or Natera?
Humana (HUM) is larger, with a market capitalization of $46.84B compared with $39.64B for Natera (NTRA).
Which stock has performed better over the past year, HUM or NTRA?
HUM returned +71.73% over the past 12 months, compared with +18.54% for NTRA (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Humana or Natera?
Humana pays a dividend yielding 0.91%, while Natera does not currently pay a regular dividend.
Are Humana and Natera in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.